Themis Medicare Share Price

Themis Medicare Limited, with its corporate operations in Mumbai, functions as a pharmaceutical company in India . The company was incorporated in 1970 . Themis Medicare manufactures and markets pharmaceutical products including anti-malarial drugs, CCD products, nutritional gummies, candy, and other products such as OD-LM, Dexem, Medzol, and Tazowin . The company serves domestic and international markets across various therapeutic segments. 

Themis Medicare share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on production volumes, raw material costs, capacity utilization rates, domestic and export demand, and the performance of its anti-malarial and nutritional product segments. Themis Medicare stock price is influenced by various factors such as earnings, regulatory approvals from health authorities, changes in drug manufacturing standards, and global generic drug demand trends. In the longer run, strategies such as product portfolio expansion, entry into new therapeutic categories, and geographic diversification affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements. 

Themis Medicare live share price provides real-time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Themis Medicare live price helps in observing short term price volatility and shows how a stock moves relative to the broader healthcare index. Furthermore, monitoring Themis Medicare stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook. 

Themis Medicare Fundamentals 

 1. Company Background

Themis Medicare Limited was incorporated in 1969 and is engaged in the development, manufacturing, and sale of pharmaceutical products. The company operates in active pharmaceutical ingredients (APIs), formulations, and contract manufacturing services. Its registered office is located in Mumbai. Over the years, it has expanded its manufacturing capabilities and product portfolio to include APIs and finished dosage forms, catering to both domestic and international pharmaceutical markets. The company is listed on Indian stock exchanges and supplies products to regulated and semi-regulated markets. 

 2. Company Product Lines

• Active Pharmaceutical Ingredients (APIs)  

• • Manufactures APIs used in pain management, anti-infective, and other therapeutic areas  

• • Supplies bulk drug ingredients to pharmaceutical companies  

• Finished Dosage Forms  

Produces tablets, injectables, and other pharmaceutical formulations  

Focuses on hospital and prescription-based products  

• Contract Manufacturing  

• • Provides manufacturing services for domestic and international pharmaceutical companies  

• • Supports formulation development and production under third-party agreements  

• Specialty Pharmaceuticals  

• • Develops niche and regulated market pharmaceutical products  

• • Includes sterile and complex injectable formulations  

 3. Company Revenue Model

• API Sales  

• • Revenue generated from sale of active pharmaceutical ingredients to domestic and global customers  

• Formulation Sales  

• • Income from branded and generic finished dosage formulations  

• Contract Manufacturing Services  

• • Earnings from third-party manufacturing agreements with pharmaceutical companies  

• Export Sales  

• • Revenue from supplying APIs and formulations to international regulated markets  

• Pricing Factors  

• • Pricing influenced by regulatory approvals, raw material costs, and global pharmaceutical demand  

 4. Geographic Presence

• Domestic Operations  

• • Headquartered in Mumbai with manufacturing and operational presence in India  

• Manufacturing Facilities  

• • Production facilities located in states such as Gujarat and Uttarakhand  

• Distribution Network  

• • Supplies pharmaceutical products across India to healthcare institutions and distributors  

• International Markets  

• • Exports APIs and formulations to regulated and semi-regulated markets including Europe and Asia  

 5. Key Milestones

• 1969: Incorporated as a pharmaceutical manufacturing company  
• Subsequent years: Expanded into APIs and formulation manufacturing  
• Recent years: Strengthened regulated market presence and upgraded manufacturing facilities  

 6. Industry Perspective

The pharmaceutical industry is driven by global healthcare demand, regulatory compliance requirements, and increasing focus on affordable medicines. Growth in the sector is supported by rising incidence of chronic diseases, expanding healthcare access, and increased outsourcing of drug manufacturing. At the same time, companies operate under strict regulatory frameworks from agencies such as the US FDA and other global authorities, which influence product approvals and export opportunities. The industry also faces pricing pressure in generic medicines and volatility in raw material costs. Continuous investment in compliance, manufacturing quality, and product development remains essential for sustained growth. 

Themis Medicare Limited Stock Market Presence: Listings & Index Representation 

Themis Medicare Limited is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) . Themis Medicare share price is available for trading on the NSE under the symbol THEMISMED and on the BSE with the scrip code 530199 . The company’s market presence is primarily within the small-cap segment of the market, classified under the Stock Style Box as ‘Small Core’ . Due to its size and sector focus, Themis Medicare stock price is generally tracked by investors interested in the specialty and generic pharmaceutical industry . 

Themis Medicare Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India . While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the BSE SmallCap, BSE Healthcare, and S&P BSE AllCap indices . Themis Medicare share price finds representation in these indices based on its market standing. This presence helps investors track the stock relative to other pharmaceutical and healthcare companies. 

Themis Medicare Limited Stock Performance and Share Price History 

Themis Medicare share price on NSE reflects its status as a pharmaceutical manufacturer in India. Performance is driven by production capacity utilization, raw material cost management, domestic distribution reach, and the company’s ability to manage operational expenses. Investors compare Themis Medicare share price today with other pharmaceutical manufacturers and generic drug producers to gauge relative performance . 

These underlying factors are often visible through real market movements across different periods. Similar trends are observed during earnings-driven movements. Broader sector strength has also played a role in supporting Themis Medicare share price. In addition to operational and sector-led factors, corporate actions such as pledging of promoter holdings can also have a significant impact on Themis Medicare share price movements short-term even when a company’s fundamentals remain strong, with promoters pledging a portion of their holdings . This shows how corporate actions can trigger short-term swings, even within a regulated pharmaceutical framework influenced by drug pricing policies and regulatory compliance. 

While short-term movements reflect events and announcements, longer-term valuation trends are visible through Themis Medicare share price 52-week high and low, providing context beyond daily or weekly changes. Based on available data, the stock’s 52-week high stood at approximately 283.95, while the 52-week low stood at approximately 98.00 . Highs suggest strong pharmaceutical demand and stable margins, while lows align with market corrections or sector volatility. These levels capture impacts of pharmaceutical policies, global generic drug trends, and earnings visibility, providing context for the stock’s historical performance. 

Themis Medicare’s stock performance reflects the trading behaviour of a small-cap pharmaceutical company operating within India’s drug manufacturing ecosystem. The company’s focused portfolio across anti-malarial drugs, CCD products, nutritional gummies, and other pharmaceutical products has shaped its Themis Medicare share price history . Over the past decade, the stock has shown periods of sharp gains and phases of consolidation. The stock delivered a positive five-year return of approximately 21.1 percent, while recording a negative one-year return of approximately 45.8 percent and a negative three-year return of approximately 13.1 percent . The stock achieved its best annual performance in 2021 with a return of approximately 162.3 percent, while the worst performance was in 2025 with a negative return of approximately 61.9 percent . From recent periods onwards, the Themis Medicare share price has shown significant correction from its 52-week highs. 

Themis Medicare’s stock performance over time has closely followed India’s pharmaceutical demand and global generic drug cycles. The Themis Medicare share price showed exceptional positive momentum in 2021, reflecting the post-pandemic demand for pharmaceutical products and the company’s strong product pipeline. However, periods of high raw material costs and competitive pressures have contributed to consolidation in Themis Medicare stock price. Over longer investment horizons, the stock has delivered a positive ten-year return of approximately 8.4 percent, though it has underperformed the broader BSE Healthcare index over the one-year, three-year, and ten-year periods . The stock has shown a total return change of approximately 702 percent since its IPO . These returns highlight the cyclical nature of the pharmaceutical industry. 

Despite COVID-19 disruptions, Themis Medicare shares showed resilience during the pandemic period. While the broader pharmaceutical sector faced challenges with supply chain disruptions and logistics, the company’s focus on essential anti-malarial and nutritional products helped the stock retain value. The company employed approximately 1,760 people as of recent data . Prudent management across its manufacturing operations kept shares stable amid the pandemic’s challenges and market volatility. 

Themis Medicare share price has seen decreases due to several recurring reasons. A decline in export demand or a drop in drug realizations directly impacts profitability and leads to selling pressure. Changes in government policy, such as stricter environmental regulations for pharmaceutical manufacturing or changes in drug price controls, can also cause the stock to fall. Furthermore, any increase in operational costs like raw material procurement or energy expenses without a matching rise in product prices squeezes the company’s margins, making the stock less attractive. Periods of global economic slowdown that affect pharmaceutical spending raise concerns about export volumes, leading to a drop in Themis Medicare share price. Broader market sell-offs in small-cap stocks also pull the price down, regardless of the company’s individual performance. A decrease in capacity utilization or lower sales in any product category directly hurts the company’s revenue, resulting in a lower valuation for Themis Medicare share price. The stock has underperformed the BSE Healthcare index by a significant margin over the one-year period . The company reported a net loss in the second and third quarters of FY 2026, which affected investor sentiment . 

Themis Medicare Limited Investor Relevance and Role in Portfolio 

Themis Medicare Limited is a holding in small-cap and pharmaceutical portfolios, offering exposure to anti-malarial drugs, nutritional gummies, and other pharmaceutical products. Inclusion in healthcare indices underscores its importance in India’s generic drug manufacturing space. The company’s diversified product portfolio, established manufacturing capabilities, and long operating history make it a consideration for long-term allocations . 

Themis Medicare share price is influenced by the company’s ownership structure. Themis Medicare equity is held by a broad mix of promoters and public investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake of approximately 67.11 percent in the company, reflecting strong internal control, though promoter holding has shown a slight decrease in recent quarters . A small portion of promoter holdings are pledged as collateral . Foreign institutional investors hold approximately 0.05 percent of the company’s shares, showing a slight decrease from previous levels . Domestic institutional investors hold approximately 0.01 percent of the company’s shares . Among mutual fund holders, Motilal Oswal BSE Healthcare ETF and Bandhan BSE Healthcare Index Fund maintain positions in the company . The public holds the remaining stake of approximately 32.84 percent in the company . This investor base with stable promoter participation underscores the company’s role as a holding in both domestic and focused portfolios concentrating on pharmaceutical manufacturing. 

Beyond fundamentals and ownership, Themis Medicare stock is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on production levels, export orders, and regulatory policy actions. The stock is available for trading on both the NSE and BSE, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements. 

Technical indicators provide additional insight into short-term momentum shifts in the company’s stock price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short-term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, the stock’s average weekly movement of approximately 6.1 percent is higher than the pharmaceuticals industry average of approximately 5.0 percent and the market average of approximately 5.2 percent . 

Based on available data, Themis Medicare share price beta stands at approximately negative 0.067, indicating that the stock generally shows negative correlation with the broader market, meaning it tends to move in the opposite direction of the market . On a daily basis, the beta values reflect specific levels of inverse correlation with market movements. Over medium-term cycles, the beta suggests relatively stable but inverse fluctuations. The stock’s average weekly movement has been stable over the past year, with volatility levels consistent with small-cap pharmaceutical stocks . Overall, Themis Medicare demonstrates a unique volatility profile compared to the broader market, with the stock generally considered to have a negative correlation with market movements, making it behave differently from typical cyclical stocks. 

Themis Medicare Limited Sectoral Relevance and Peer Positioning 

Themis Medicare Limited sector relevance stems from its presence in the pharmaceutical manufacturing industry, its portfolio of anti-malarial drugs, CCD products, nutritional gummies, candy, and other pharmaceutical products including OD-LM, Dexem, Medzol, and Tazowin, and its sales across both domestic and international markets, establishing it as a focused small-cap pharmaceutical provider supporting India’s generic drug manufacturing ecosystem . Peer comparisons with companies like Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Cipla, and other pharmaceutical manufacturers focus on production capacity, product mix, regulatory compliance, and geographical presence rather than short-term stock moves . These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of pharmaceutical demand, generic drug trends, and regulatory compliance further highlights Themis Medicare positioning within India’s broader pharmaceutical manufacturing market. 

Themis Medicare P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from pharmaceutical product sales. In earlier years, the ratio remained at certain levels, indicating measured market expectations. Based on available data, the current P/E ratio has shown variation, with some sources reporting a TTM P/E of approximately negative 31.88 due to recent losses, while other sources indicate a P/E of approximately 56.40 based on annual earnings . The company’s net profit has shown a decreasing trend in recent years, with profit after tax decreasing from approximately 61.56 crore rupees in FY 2022 to approximately 23.92 crore rupees in FY 2025 . Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a cyclical industry. 

Alongside valuation, Themis Medicare EPS provides insight into its operational performance and income generation from anti-malarial drugs, nutritional gummies, CCD products, and other pharmaceutical products . Between earlier fiscal years, earnings per share reflected periods of growth followed by moderation. Based on available data, the company reported an adjusted EPS of approximately 2.5 in FY 2025, compared to 2.6 in FY 2024 and 4.5 in FY 2023 . The company’s EPS has shown a declining trend, with a 5-year CAGR of approximately 7.7 percent . In recent quarters, the company reported negative EPS, reflecting challenging operating conditions . More recent quarterly performance suggests that EPS remains under pressure. 

Themis Medicare market cap highlights its position as a small-cap player within India’s pharmaceutical sector. Based on recent data, the company’s market capitalization stands at approximately 727 to 941 crore rupees depending on the reporting period . The company’s market cap has fluctuated in line with investor perceptions of the company’s growth potential following its strong performance in 2021 and subsequent correction. From earlier years through more recent periods, the market cap showed an increasing trend followed by significant correction. This pattern reflects strong investor confidence during favorable pharmaceutical cycles followed by contraction during challenging periods. This decrease mirrors the correction in the Themis Medicare share price and the broader performance of the pharmaceutical sector relative to broader market indices. 

Finally, Themis Medicare earnings trajectory demonstrates the impact of its operational execution in a competitive industry. In recent fiscal years, total income showed growth supported by the core pharmaceutical business. Based on available data, the company’s revenue increased from approximately 386.52 crore rupees in FY 2024 to approximately 410.18 crore rupees in FY 2025, a growth of approximately 6.12 percent . However, net profit decreased from approximately 24.75 crore rupees in FY 2024 to approximately 23.92 crore rupees in FY 2025, a decline of approximately 3.34 percent . The company’s operating profit margin decreased from approximately 13.5 percent in FY 2024 to approximately 12.1 percent in FY 2025 . The company has faced headwinds from fluctuating raw material prices, increased competitive pressures, and margin compression. These developments illustrate the cyclical nature of the pharmaceutical industry and the company’s position within this sector. 

Summary 

Themis Medicare Limited operates as a pharmaceutical manufacturer producing anti-malarial and nutritional products for domestic and international markets. Themis Medicare share price moves largely with pharmaceutical demand cycles, raw material costs, and broader healthcare sector conditions. Themis Medicare stock price reflects its specific position within the small-cap pharmaceutical manufacturing space. The company’s performance aligns with the operational results of its focused product portfolio and manufacturing capabilities.